1. Home
  2. PDC vs LTRN Comparison

PDC vs LTRN Comparison

Compare PDC & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PDC

Perpetuals.com Ltd American Depositary Shares

N/A

Current Price

$7.10

Market Cap

23.7M

Sector

Technology

ML Signal

N/A

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$3.03

Market Cap

22.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDC
LTRN
Founded
2018
2013
Country
Japan
United States
Employees
20
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.7M
22.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PDC
LTRN
Price
$7.10
$3.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
130.1K
278.3K
Earning Date
07-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.65
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.46
$1.11
52 Week High
$8.40
$5.74

Technical Indicators

Market Signals
Indicator
PDC
LTRN
Relative Strength Index (RSI) 48.62 66.85
Support Level $4.48 $3.04
Resistance Level $7.90 $3.09
Average True Range (ATR) 0.77 0.28
MACD -0.20 0.11
Stochastic Oscillator 39.31 84.21

Price Performance

Historical Comparison
PDC
LTRN

About PDC Perpetuals.com Ltd American Depositary Shares

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Share on Social Networks: